tiprankstipranks
Trinity Biotech Advances in Diabetes Monitoring Tech
Company Announcements

Trinity Biotech Advances in Diabetes Monitoring Tech

Trinity Biotech (TRIB) has released an update.

Pick the best stocks and maximize your portfolio:

Trinity Biotech plc has reported successful pre-pivotal trial results for its innovative continuous glucose monitor (CGM) technology following its acquisition of Waveform Technologies’ assets. This new CGM system boasts enhanced accuracy, a user-friendly modular design, and cost-effective operation aimed at revolutionizing diabetes management. With the positive trial outcomes, Trinity Biotech is moving forward with further trials, setting the stage for a pivotal trial in 2025, and aims to capture a significant share of the rapidly growing CGM market.

For further insights into TRIB stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskTrinity Biotech Gains WHO Approval for Offshore HIV Test Manufacturing
TheFlyTrinity Biotech gets approval from WHO for TrinScreen, Uni-Gold manufacturing
TipRanks Auto-Generated NewsdeskTrinity Biotech Files Prospectus for $1 Million ADS Offering
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App